COVID-19 pandemic
Sanofi and GlaxoSmithKline delays a launch of adjuvanted recombinant protein-based of COVID-19 vaccine programme until end of 2021.
Sources: France 24
Changes
- Sanofi and GSK delays a launch of adjuvarned recombinant protein-based of COVID-19 vaccine programme until end of 2021.
- Sanofi and GlaxoSmithKline delays a launch of adjuvarned recombinant protein-based of COVID-19 vaccine programme until end of 2021.
- Sanofi and GlaxoSmithKline delays a launch of adjuvanted recombinant protein-based of COVID-19 vaccine programme until end of 2021.